{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:46:33Z","timestamp":1787600793945,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-04470-9","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T02:29:47Z","timestamp":1736389787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Left ventricular hypertrophy in young hypertensives: the possible crosstalk of mTOR and angiotensin-II -a case-control study"],"prefix":"10.1186","volume":"25","author":[{"given":"Busayo Onafowoke","family":"Oguntola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Olawale","family":"Oguntola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opeyemi Ezekiel","family":"Ojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauleen Ayomide","family":"Ukpabio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adams Olalekan","family":"Omoaghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehinde Samuel","family":"Olaniyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"issue":"1","key":"4470_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1161\/HYPERTENSIONAHA.121.18192","volume":"79","author":"A Al-Makki","year":"2022","unstructured":"Al-Makki A, DiPette D, Whelton PK, Murad MH, Mustafa RA, Acharya S, et al. Hypertension pharmacological treatment in adults: a World Health Organization Guideline Executive Summary. Hypertension. 2022;79(1):293\u2013301.","journal-title":"Hypertension"},{"issue":"1","key":"4470_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/HYPERTENSIONAHA.119.13820","volume":"75","author":"TC Hinton","year":"2020","unstructured":"Hinton TC, Adams ZH, Baker RP, Hope KA, Paton JFR, Hart EC, et al. Investigation and treatment of high blood pressure in Young People. Hypertension. 2020;75(1):16\u201322.","journal-title":"Hypertension"},{"issue":"5","key":"4470_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41371-020-00427-x","volume":"35","author":"SK Nadar","year":"2021","unstructured":"Nadar SK, Lip GYH. The heart in hypertension. J Hum Hypertens. 2021;35(5):383\u20136.","journal-title":"J Hum Hypertens"},{"issue":"1","key":"4470_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.pcad.2019.11.009","volume":"63","author":"M Yildiz","year":"2020","unstructured":"Yildiz M, Oktay AA, Stewart MH, Milani RV, Ventura HO, Lavie CJ. Left ventricular hypertrophy and hypertension. Prog Cardiovasc Dis. 2020;63(1):10\u201321.","journal-title":"Prog Cardiovasc Dis"},{"issue":"21","key":"4470_CR5","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.3390\/cells11213336","volume":"11","author":"SK Bhullar","year":"2022","unstructured":"Bhullar SK, Dhalla NS. Angiotensin II-Induced Signal Transduction mechanisms for Cardiac Hypertrophy. Cells. 2022;11(21):3336.","journal-title":"Cells"},{"issue":"11","key":"4470_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40267-020-00769-z","volume":"36","author":"SN Ahmed","year":"2020","unstructured":"Ahmed SN, Jhaj R, Sadasivam B, Joshi R. The role of renin\u2013angiotensin\u2013aldosterone system inhibition in the regression of hypertensive left ventricular hypertrophy: the evidence of the last three decades. Drugs Therapy Perspect. 2020;36(11):509\u201317.","journal-title":"Drugs Therapy Perspect"},{"issue":"14","key":"4470_CR7","doi-asserted-by":"publisher","first-page":"11497","DOI":"10.3390\/ijms241411497","volume":"24","author":"F Shi","year":"2023","unstructured":"Shi F, Collins S. Regulation of mTOR Signaling: emerging role of cyclic nucleotide-dependent protein kinases and implications for Cardiometabolic Disease. Int J Mol Sci. 2023;24(14):11497.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"4470_CR8","doi-asserted-by":"publisher","first-page":"13628","DOI":"10.3390\/ijms241713628","volume":"24","author":"A Das","year":"2023","unstructured":"Das A, Reis F. mTOR Signaling: New insights into Cancer, Cardiovascular diseases, Diabetes and Aging. Int J Mol Sci. 2023;24(17):13628.","journal-title":"Int J Mol Sci"},{"issue":"23","key":"4470_CR9","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1016\/j.jacc.2020.04.038","volume":"75","author":"C Wang","year":"2020","unstructured":"Wang C, Yuan Y, Zheng M, Pan A, Wang M, Zhao M, et al. Association of Age of Onset of Hypertension with Cardiovascular diseases and Mortality. J Am Coll Cardiol. 2020;75(23):2921\u201330.","journal-title":"J Am Coll Cardiol"},{"key":"4470_CR10","doi-asserted-by":"publisher","first-page":"993513","DOI":"10.3389\/fcvm.2022.993513","volume":"9","author":"MD Sinha","year":"2022","unstructured":"Sinha MD, Azukaitis K, Sladowska-Koz\u0142owska J, B\u00e5rdsen T, Merkevicius K, Karlsen Sletten IS, et al. Prevalence of left ventricular hypertrophy in children and young people with primary hypertension: Meta-analysis and meta-regression. Front Cardiovasc Med. 2022;9:993513.","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"4470_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.5455\/medarh.2020.74.428-432","volume":"74","author":"RB Altaweel","year":"2020","unstructured":"Altaweel RB, Radhi MA. Assessment of Left ventricular hypertrophy (LVH) criteria by Surface Electrocardiography in a sample of Iraqi patients with systemic arterial hypertension. Med Archives. 2020;74(6):428.","journal-title":"Med Archives"},{"key":"4470_CR12","doi-asserted-by":"crossref","unstructured":"Kristensen CB, Steensgaard-Hansen F, Myhr KA, L\u00f8kkegaard NJ, Finsen SH, Hassager C et al. Left ventricular Mass Assessment by 1- and 2-Dimensional echocardiographic methods in Hemodialysis patients: changes in left ventricular volume using Echocardiography before and after a Hemodialysis Session. Kidney Med.2020; 2(5): 578\u201388.","DOI":"10.1016\/j.xkme.2020.06.006"},{"issue":"3","key":"4470_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/jcp-2022-208480","volume":"76","author":"J Martins","year":"2023","unstructured":"Martins J, Steyn N, Rossouw HM, Pillay TS. Best practice for LDL-cholesterol: when and how to calculate. J Clin Pathol. 2023;76(3):145\u201352.","journal-title":"J Clin Pathol"},{"key":"4470_CR14","unstructured":"Bornstein AB, Rao SS, Marwaha K, Left Ventricular H. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan\u2013. PMID: 32491466."},{"issue":"12","key":"4470_CR15","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension the Task Force for the management of arterial hypertension of the European Society of Hypertension. J Hypertens. 2023;41(12):1874\u20132071.","journal-title":"J Hypertens"},{"issue":"22","key":"4470_CR16","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1161\/CIRCULATIONAHA.119.044838","volume":"141","author":"H Lee","year":"2020","unstructured":"Lee H, Yano Y, Cho SMJ, Park JH, Park S, Lloyd-Jones DM, et al. Cardiovascular Risk of isolated systolic or diastolic hypertension in young adults. Circulation. 2020;141(22):1778\u201386.","journal-title":"Circulation"},{"issue":"4","key":"4470_CR17","first-page":"e37467","volume":"15","author":"M Meher","year":"2023","unstructured":"Meher M, Pradhan S, Pradhan SR. Risk factors Associated with hypertension in young adults: a systematic review. Cureus. 2023;15(4):e37467.","journal-title":"Cureus"},{"issue":"8","key":"4470_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.tips.2023.06.001","volume":"44","author":"S Bouffette","year":"2023","unstructured":"Bouffette S, Botez I, De Ceuninck F. Targeting galectin-3 in inflammatory and fibrotic diseases. Trends Pharmacol Sci. 2023;44(8):519\u201331.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"4470_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/biom12010046","volume":"12","author":"G Sygitowicz","year":"2021","unstructured":"Sygitowicz G, Maciejak-Jastrz\u0119bska A, Sitkiewicz D. The diagnostic and therapeutic potential of galectin-3 in cardiovascular diseases. Biomolecules. 2021;12(1):46.","journal-title":"Biomolecules"},{"key":"4470_CR20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.36660\/abc.20210868","volume":"117","author":"CL Cunha","year":"2021","unstructured":"Cunha CL. Electrocardiographic diagnosis of left ventricular hypertrophy. Arquivos brasileiros de cardiologia. 2021;117:932\u20133.","journal-title":"Arquivos brasileiros de cardiologia"},{"issue":"6","key":"4470_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/jhh.2011.104","volume":"26","author":"C Cuspidi","year":"2012","unstructured":"Cuspidi C, Sala C, Negri F, Mancia G, Morganti A. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens. 2012;26(6):343\u20139.","journal-title":"J Hum Hypertens"},{"issue":"7","key":"4470_CR22","doi-asserted-by":"publisher","first-page":"102576","DOI":"10.1016\/j.cpcardiol.2024.102576","volume":"49","author":"M Hussein","year":"2024","unstructured":"Hussein M, Muyinda A, Olet SC, Hersi AM, Said AI, Elmi HSA. Prevalence rate of left ventricular hypertrophy and the burden of arrhythmias among hypertensive patients attending Jinja regional referral hospital, eastern Uganda. Curr Probl Cardiol. 2024;49(7):102576.","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"4470_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/jcm12010228","volume":"12","author":"A Apitz","year":"2022","unstructured":"Apitz A, Socrates T, Burkard T, Mayr M, Vischer AS. Prevalence and characterisation of severe left ventricular hypertrophy diagnosed by echocardiography in hypertensive patients. J Clin Med. 2022;12(1):228.","journal-title":"J Clin Med"},{"issue":"1","key":"4470_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jcdr.2013.02.005","volume":"4","author":"O Ogunlade","year":"2013","unstructured":"Ogunlade O, Akintomide AO. Assessment of voltage criteria for left ventricular hypertrophy in adult hypertensives in south-western Nigeria. J Cardiovasc Dis Res. 2013;4(1):44\u20136.","journal-title":"J Cardiovasc Dis Res"},{"issue":"3","key":"4470_CR25","first-page":"1","volume":"3","author":"MA Ngabea","year":"2022","unstructured":"Ngabea MA, Ojji DB, Umar H, Isezuo SA. Prevalence of echocardiographic left ventricular hypertrophy among hypertensives in a tertiary health institution in Nigeria. Ann Med Res Pract. 2022;3(3):1\u20135.","journal-title":"Ann Med Res Pract"},{"key":"4470_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jelectrocard.2022.11.004","volume":"76","author":"SA Amidou","year":"2023","unstructured":"Amidou SA, Houehanou YC, Gbaguidi GN, Lacroix P, Aboyans V, Sonou A, et al. Normal limits of electrocardiogram in africans and their consequences on the prevalence of left ventricular hypertrophy in hypertensive individuals: insights from the TAHES study. J Electrocardiol. 2023;76:71\u20138.","journal-title":"J Electrocardiol"},{"issue":"4","key":"4470_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.5603\/ah.96273","volume":"27","author":"S Salamaga","year":"2023","unstructured":"Salamaga S, Juszczyk I, Dydowicz F, Matyjasek M, Turowska A, Lipski D, et al. Evaluation of sensitivity and specificity of ECG left ventricular hypertrophy criteria in obese and hypertensive patients. Arterial Hypertens. 2023;27(4):223\u201331.","journal-title":"Arterial Hypertens"},{"issue":"6","key":"4470_CR28","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1161\/01.CIR.103.6.836","volume":"103","author":"J Sundstr\u00f6m","year":"2001","unstructured":"Sundstr\u00f6m J, Lind L, Vessby B, Andr\u00e9n B, Aro A, Lithell HO. Dyslipidemia and an unfavorable fatty acid Profile Predict Left ventricular hypertrophy 20 years later. Circulation. 2001;103(6):836\u201341.","journal-title":"Circulation"},{"issue":"2","key":"4470_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.24920\/004066","volume":"37","author":"X Huang","year":"2022","unstructured":"Huang X, Deng K, Qin J, Lei F, Zhang X, Wang W, Lin L, Zheng Y, Yao D, Lu H, Liu F. Association between lipid profiles and left ventricular hypertrophy: new evidence from a retrospective study. Chin Med Sci J. 2022;37(2):103\u201317.","journal-title":"Chin Med Sci J"},{"issue":"1","key":"4470_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41598-023-51085-1","volume":"14","author":"S Ikeda","year":"2024","unstructured":"Ikeda S, Shinohara K, Tagawa K, Tohyama T, Kishimoto J, Kazurayama M, Tanaka S, Yamaizumi M, Nagayoshi H, Toyama K, Matsushima S. Association of baseline electrocardiographic left ventricular hypertrophy with future renal function decline in the general population. Sci Rep. 2024;14(1):301.","journal-title":"Sci Rep"},{"issue":"1","key":"4470_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.numecd.2020.08.028","volume":"31","author":"E Nardi","year":"2021","unstructured":"Nardi E, Mul\u00e8 G, Giammanco A, Mattina A, Geraci G, Nardi C, et al. Left ventricular hypertrophy in chronic kidney disease: a diagnostic criteria comparison. Nutr Metabolism Cardiovasc Dis. 2021;31(1):137\u201344.","journal-title":"Nutr Metabolism Cardiovasc Dis"},{"issue":"1","key":"4470_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/metabo13010087","volume":"13","author":"S Stanciu","year":"2023","unstructured":"Stanciu S, Rusu E, Miricescu D, Radu AC, Axinia B, Vrabie AM, et al. Links between metabolic syndrome and hypertension: the relationship with the current antidiabetic drugs. Metabolites. 2023;13(1):87.","journal-title":"Metabolites"},{"key":"4470_CR33","doi-asserted-by":"crossref","unstructured":"Dorobantu M, V\u00eej\u00eeiac A. Myocardial ischemia: a link between hypertension and heart failure. InHypertension and Heart failure: Epidemiology, mechanisms and Treatment 2024 Mar 5 (pp. 155\u201367). Cham: Springer International Publishing.","DOI":"10.1007\/978-3-031-39315-0_11"},{"issue":"2","key":"4470_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1139\/cjpp-2019-0566","volume":"98","author":"CJ Oldfield","year":"2020","unstructured":"Oldfield CJ, Duhamel TA, Dhalla NS. Mechanisms for the transition from physiological to pathological cardiac hypertrophy. Can J Physiol Pharmacol. 2020;98(2):74\u201384.","journal-title":"Can J Physiol Pharmacol"},{"issue":"11","key":"4470_CR35","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.3390\/biomedicines10112970","volume":"10","author":"MT Macvanin","year":"2022","unstructured":"Macvanin MT, Rizzo M, Radovanovic J, Sonmez A, Paneni F, Isenovic ER. Role of chemerin in cardiovascular diseases. Biomedicines. 2022;10(11):2970.","journal-title":"Biomedicines"},{"issue":"1","key":"4470_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4103\/njc.njc_20_18","volume":"16","author":"N Hanboly","year":"2019","unstructured":"Hanboly N, Sharaf Y, Al-Anany M, Saeed E. Serum chemerin as a predictor of left ventricle hypertrophy in patients with coronary artery disease. Nigerian J Cardiol. 2019;16(1):25.","journal-title":"Nigerian J Cardiol"},{"key":"4470_CR37","doi-asserted-by":"crossref","unstructured":"Bhullar SK, Shah AK, Dhalla NS. Role of angiotensin II in the development of subcellular remodeling in heart failure. Explor Med. 2021;352\u201371.","DOI":"10.37349\/emed.2021.00054"},{"issue":"1","key":"4470_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/vhrm.2008.04.01.67","volume":"4","author":"C Cuspidi","year":"2008","unstructured":"Cuspidi C, Negri F, Zanchetti A. Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention. Vasc Health Risk Manag. 2008;4(1):67\u201373.","journal-title":"Vasc Health Risk Manag"},{"key":"4470_CR39","doi-asserted-by":"publisher","first-page":"746382","DOI":"10.3389\/fcvm.2021.746382","volume":"8","author":"M Mohan","year":"2021","unstructured":"Mohan M, Dihoum A, Mordi IR, Choy AM, Rena G, Lang CC. Left ventricular hypertrophy in diabetic cardiomyopathy: a target for intervention. Front Cardiovasc Med. 2021;8:746382.","journal-title":"Front Cardiovasc Med"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04470-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04470-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04470-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T03:02:11Z","timestamp":1736391731000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04470-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4470"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04470-9","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the ethics and research committee of ABUAD Multisystem Hospital (AMSH\/REC\/BOO\/184), Ado-Ekiti; Ekiti State University Teaching Hospital Ado-Ekiti (EKSUTH\/A67\/2023\/11\/005) and Federal Teaching Hospital, Ido-Ekiti (ERC\/2024\/01\/15\/1066B) respectively.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}